CAJ | 학술논문

贝伐珠单抗在肿瘤靶向治疗中已广泛应用，其最常见不良反应为肾脏损害，表现为蛋白尿，主要机制可能有干扰足细胞-内皮血管内皮生长因子（VEGF）轴信号、继发性高血压致肾小球内压增加、内皮受损引起亚急性肾小球血栓性微血管病等。肾脏病理表现以血栓性微血管病为主，其他少见类型包括肾小球病变、肾间质病变、良性肾小球动脉硬化等。故贝伐珠单抗使用期间应密切监测尿蛋白和肾功能变化，及时治疗、减少药物剂量甚至停药，保护患者肾功能。
패벌주단항재종류파향치료중이엄범응용，기최상견불량반응위신장손해，표현위단백뇨，주요궤제가능유간우족세포-내피혈관내피생장인자（VEGF）축신호、계발성고혈압치신소구내압증가、내피수손인기아급성신소구혈전성미혈관병등。신장병리표현이혈전성미혈관병위주，기타소견류형포괄신소구병변、신간질병변、량성신소구동맥경화등。고패벌주단항사용기간응밀절감측뇨단백화신공능변화，급시치료、감소약물제량심지정약，보호환자신공능。
Bevacizumab has been widely used in tumor targeting therapy,while the most common adverse reaction is renal impairment,manifested as proteinuria. The main mechanisms may include interfering podocytes-endothelial vascular endothelial growth factor(VEGF)axis signals,increasing glomerular pressure caused by secondary hypertension,subacute renal thrombotic microangiopathy caused by endothelial damage and so on. Thrombotic microangiopathy is the main renal pathological type,and other rare types include glomer-ular lesions,renal interstitial disease,and benign renal arteriolar nephrosclerosis. Therefore,urine protein excretion and renal function should be closely monitored during bevacizumab treatment period for timely treat-ment,dose reduction or even withdrawal if necessary to ensure renal function.